Abstract: The present invention relates to a feed supplement which comprises a resin acid based composition comprising over 10% (w/w) resin acids for use in the prevention of growth of harmful bacteria in the animal digestive tract, in the prevention of intestinal disorders, in the modulation of microbial population of the animal digestive tract, in enhancing rumen fermentation, lowering rumen methane production and/or in binding toxins. The invention further relates to a use of the feed supplement and a feed composition comprising the feed supplement.

Abstract: Disclosed herein are new compositions having combinations of purified cannabinoids. One embodiment of this disclosure provides compositions having one or more purified cannabinoids in combination with a purified terpene. One embodiment of this disclosure provides compositions having one or more purified cannabinoids in combination with a purified flavonoid. One embodiment of this disclosure provides compositions having one or more purified cannabinoids in combination with a purified mineral.

Abstract: A herbal composition for diabetic retinopathy includes 40 wt % of an ethanol extract of Astragalus membranaceus, 8 wt % of an ethanol extract of Angelica sinensis and 52 wt % of a water extract of Dendrobium officinale. The present invention further relates to a method for diabetic retinopathy by administrating the herbal composition to a subject in need.

Abstract: The present invention relates to a phytocomplex or natural concentrate rich in polyphenolic compounds, such as hydroxytyrosol and 3,4-DHPA-EDA, derived from the vegetation waters of oil-bearing olives or from olive pomace resulting from the olive milling process for use in the treatment and prevention of angiogenesis and inflammation. In particular, the angiogenesis and inflammation to which reference is made is pathologic angiogenesis and inflammation, for example that which sustains the development and spread of a tumor or angiogenesis and inflammation tied to non-tumor pathologies. The present invention further relates to a beverage comprising the polyphenol concentrate and the use thereof in the treatment and prevention of angiogenesis and inflammation.

Abstract: Composition and methods for treating brain “plaques” and “tangles” in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and an oolong tea extract.

Abstract: Present invention discloses an oil palm composition for use in prevention or treatment of Alzheimer's disease. The composition is useful in impeding formation of neurotoxic peptide. Present invention can be used in preparation of a medicament in a therapeutic effective amount for prevention or treatment of Alzheimer's disease and diseases related thereto.

Abstract: A method for manufacturing an extract of Zingiber zerumbet, which is used to manufacture the extract of Zingiber zerumbet for diabetic retinopathy, includes: soaking a raw sample of Zingiber zerumbet with vinegar for 8 hours; boiling the soaked product at 1.5-2.5 kg/m2, 95-105° C. for 30 minutes to obtain a processed sample of Zingiber zerumbet; and extracting the processed sample of Zingiber zerumbet with an extractant being water or 95% ethanol at 70-90° C. for 8 hours to obtain the extract of Zingiber zerumbet. The present invention further relates to the extract of Zingiber zerumbet and a method for diabetic retinopathy by administrating the extract of Zingiber zerumbet to a subject in need.

Abstract: An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R4 is lower alkyl, R3 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

Abstract: A method for preventing, inhibiting or treating nausea and/or vomiting in a mammalian subject, the method comprising administering an effective amount of a peripherally-restricted kappa opioid receptor agonist to the subject. The nausea and/or vomiting can be associated with use of an opioid, such as morphine or fentanyl. The peripherally-restricted kappa opioid receptor agonist can be an L-amino acid-containing peptide, a D-amino acid-containing peptide, or a synthetic peptide amide, such as for instance, D-Phe-D-Phe-D-Leu-D-Lys-[?(4-aminopiperidine-4-carboxylic acid)]-OH (CR845).

Abstract: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of viral disease.

Abstract: The present invention relates to a composition for treating and preventing benign prostatic hyperplasia, and a method for treating benign prostatic hyperplasia using same. More specifically, the present invention relates to a composition comprising telomerase-derived peptides for effectively treating and preventing benign prostatic hyperplasia and a method for treating benign prostatic hyperplasia using same. The composition comprising the peptide according to the present invention exhibits excellent effectiveness in treating and preventing benign prostatic hyperplasia.

Abstract: The present invention provides cyclic compounds that are useful in preventing or treating atherosclerosis or related disorders. The invention also provides therapeutic methods for treating or preventing various diseases or disorders associated with or mediated by atherosclerosis. Further provided in the invention are methods of screening for anti-atherosclerotic cyclic peptides with improved properties.

Abstract: The present invention relates to a composition for preventing, alleviating or treating obesity comprising a partial fragment of HIV-1 (Human Immunodeficiency Virus-1) Tat (Trans activator of transcription) protein. The peptides of the present invention induce anorexia and increase lipolysis, ?-oxidation of free fatty acids, thermogenesis, and total energy expenditure, therefore may be effectively used for preventing or treating diseases related to metabolic imbalance such as obesity.

Abstract: The present inventions relates to the use of an isolated nucleic acid molecule comprising a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence complementary to said nucleotide sequence, for treating or ameliorating blindness. The light-gated ion channel or pump gene can be a halorhodopsin gene.

Abstract: Provided are compositions and methods for prophylaxis and/or therapy of C. difficile infection, and for inhibiting dissemination of C. difficile spores. The compositions contain C. difficile proteins, including distinct proteins and fusions of C. difficile CD 1067, BclA1, SleC, CotA, Spl7, FliC, FliD, CD toxin A, CD toxin B, and combinations thereof. The methods include prophylaxis and/or therapy of C. difficile infection by administering to a subject in need a composition that includes the C. difficile protein(s).

Abstract: A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analogue or variant thereof, and a method of making such a stent.

Abstract: The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-arg sequence or an arginine-rich peptide.

Abstract: Disclosed are mixed solutions of PRG4 and hyaluronic acids having controlled, enhanced rheological properties adapted for various particular medical and cosmetic uses. Such solutions combine the solution-based lubrication ability of HA and the boundary-based lubricating effects of lubricin. Being more viscous, the solutions when used for joint viscosupplementation enhance both the duration of the HA within the joint capsule (in vivo half-life) and enhance the cushioning effects of the HA, as well as improve both solution and boundary mode lubrication mechanisms.

Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of FGFR signaling.

Abstract: The present invention relates to a pharmaceutical composition for the regeneration of nerves comprising Vax protein as an active ingredient. Vax1 is secreted in the ventral hypothalamus (vHT) explant separated from a mouse. The secreted Vax1 combines with extracellular sugar group of heparan sulfate proteoglycans (HSPGs) existing in retinal ganglion cell (RGC) axon of the retinal explant co-cultured so as for the complex invades into axonplasm. Then, the Vax1 conjugated with the sugar group activates the local protein synthesis to accelerate the growth of retinal ganglion cell axon. In some embodiments, Vax protein or a nucleic acid encoding the protein, can be used in a pharmaceutical composition for the regeneration of nerves.

Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.

Abstract: It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic.

Abstract: The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide encoding the isoforms. The composition of the present invention is used to effectively prevent or treat amyotrophic lateral sclerosis.

Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.

Abstract: The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects. The means for solving the problem is a skin external-preparation composition, in particular, a therapeutic agent for dermatitis or a skin texture-improving agent, having C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

Abstract: A composition-of-matter for treating cardiovascular disorders and a method of using same are provided The composition-of-matter includes a leptin antagonist and a carrier configured for localized release of the leptin antagonist.

Abstract: The present invention relates to a stable composition for gonadotropins. It provides a composition useful for stabilization of gonadotropins while preventing aggregation, dissociation, fragmentation and formation of oxidized species variants in solution for injection. Thus, it prevents instability of protein or polypeptide molecules caused due to aggregation or fragmentation or oxidation during or after formulation. Also, it provides a pharmaceutical composition of gonadotropins, which can be therapeutically used for the treatment of various indications either in single-dose form or in multi-dose form.

Abstract: The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.

Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.

Abstract: The present invention relates to methods, compositions, and devices for the transdermal delivery of therapeutic agents and cosmetic agents in inclusion body form. Such inclusion bodies can deliver therapeutic and cosmetic agents through the skin barrier and reach locations deep in the skin. The disclosed compositions can be used to treat skins diseases and conditions.

Abstract: The invention relates to the field of medicine and in particular to means and methods for preserving renal function after a treatment with a risk of reducing renal function. The present invention also relates to means and methods for shortening the duration of renal replacement therapy, increasing the creatinine clearance and decreasing the adverse effects of medicaments.

Abstract: A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.

Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.

Abstract: Methods for treating rhinitis in a subject are provided herein. The methods of the present invention comprise intranasal administration of a topical composition comprising a purified botulinum neurotoxin, a carrier and a viscosity modifier to one or more inner surfaces of the nose. The methods disclosed herein provide alternative methods for delivery of botulinum neurotoxin to the nasal anatomy for the treatment of rhinitis.

Abstract: Methods and compositions are provided to modulate the activity of Perforin-2. Provided herein are various components of the Perforin-2 activation pathway. In specific embodiments, inhibitors of the various components of the Perforin-2 activation pathway are provided which may be employed in various methods, including, but not limited to, the diagnosis and treatment of diseases associated with gut inflammation. Methods of screening for Perforin-2 inhibitors are also provided. Further provided are compounds that increase the ubiquitination of Perforin-2 and thereby increase Perforin-2 activity. Various methods for increasing Perforin-2 activity and for the treatment of infectious disease, in particular bacteria and antibiotic-resistant bacteria, are also provided.

Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

Abstract: Disclosed is the novel use of some Aza-podophyllotoxin derivatives (AZPs) for modulation of the immune system (immunomodulation), including a method for modulating an immune response comprising administering to a subject an effective amount of at least one Aza-podophyllotoxin derivative of general formula wherein A-ring is selected from the group consisting of 1,3-dioxolane, cyclopentane, 1,4-dioxane, one methoxy, two methoxys, and ethyl; and wherein E-ring is selected from the group consisting of dimethoxyanisole, veratrol, anisole, benzene, syringol, bromobenzene, chlorobenzene, 1,2-dichlorobenzene, 2,3-dimethoxybenzene, 3,4,5-trimethoxybenzene.

Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases.

Abstract: Compositions and methods for delivering tumor associated antigens and immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer.

Abstract: AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.

Abstract: The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.

Abstract: The invention relates to an antigenic composition or vaccine comprising a viral vector, the viral vector comprising nucleic acid encoding Plasmodium protein PfLSA1, or a part or variant of Plasmodium protein PfLSA1; PfLSAP2, or a part or variant of Plasmodium protein PfLSAP2; PfUIS3, or a part or variant of Plasmodium protein PfUIS3; PfI0580c, or a part or variant of Plasmodium protein PfI0580c; and PfSPECT-1, or a part or variant of Plasmodium protein PfSPECT-1.

Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.

Abstract: The present invention relates to protecting against, treating, and detecting Fusobacteria infections. Compositions and methods derived from nucleic acid and protein sequences of a 40 kDa Adhesin protein are provided to protect against, treat, and detect Fusobacteria infections in a subject. In one aspect, vaccines capable of inducing an immune response to a 40 kDa Adhesin protein are used to protect against Fusobacteria infection. Also, nucleic acid molecules, proteins, immunogens, antibodies, and antisense molecules derived from the sequences of the 40 kDa Adhesin protein may be used to protect against, treat, and detect Fusobacteria infections in a subject.

Abstract: Peptides and compositions for a therapeutic vaccine to treat persons infected with human papilloma virus are presented. Methods of using the compositions and treating persons infected with human papilloma virus, including those at risk of cancer or already with cancer from human papilloma virus, are presented.

Abstract: The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2 polypeptide. Moreover, the present invention relates to a vaccine comprising said immunogenic polypeptide. The present invention is also concerned with a method for producing an antibody against human papillomavirus. Also encompassed by the present invention is an antibody obtained by carrying out the said method.

Abstract: The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by SBV.

Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.